目的 探讨癃清片联合诺氟沙星治疗慢性前列腺炎的临床效果与安全性。方法 选取2016年9月—2018年9月于重庆市第十三人民医院诊治的慢性前列腺炎患者165例，随机分成对照组（82例）和治疗组（83例）。对照组口服诺氟沙星胶囊，4粒/次，2次/d；治疗组患者在对照组基础上口服癃清片，6片/次，2次/d。两组患者均连续治疗28 d。观察两组患者临床疗效，同时比较治疗前后两组患者症状积分、白细胞介素-10（IL-10）、分泌型免疫球蛋白A（SIgA）和血管细胞黏附分子-1（VCAM-1）水平及不良反应情况。结果 治疗后，对照组临床有效率为87.80%，显著低于治疗组的97.59%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组慢性前列腺炎症状积分均显著降低（P<0.05），且治疗组这些症状积分明显低于对照组（P<0.05）。治疗后，两组患者前列腺液中IL-10、SIgA以及VCAM-1水平均显著降低（P<0.05），且治疗组IL-10、SIgA以及VCAM-1水平明显低于对照组（P<0.05）。治疗期间，对照组患者不良反应发生率为10.98%，显著高于治疗组的2.41%，两组比较差异具有统计学意义（P<0.05）。结论 癃清片联合诺氟沙星治疗慢性前列腺炎疗效显著，安全可靠，具有一定的临床推广应用价值。

Objective To investigate the clinical effect and safety of Longqing Tablets combined with norfloxacin in treatment of chronic prostatitis. Methods Patients (165 cases) with chronic prostatitis in the Thirteenth People's Hospital of Chongqing from September 2016 to September 2018 were randomly divided into control (82 cases) and treatment (83 cases) groups. Patients in the control group were po administered with Norfloxacin Capsules, 4 grains/time, twice daily. Patients in the treatment group were po administered with Longqing Tablets on the basis of the control group, 6 tablets/time, twice daily. Patients in two groups were treated for 28 d. After treatment, the clinical efficacy was evaluated, and the symptoms scores, IL-10, SIgA and VCAM-1 levels of prostatic fluid, adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 87.80%, which was significantly lower than 97.59% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the symptoms scores of chronic prostatitis in two groups were significantly decreased (P<0.05), and these scores in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, IL-10, SIgA and VCAM-1 levels of prostatic fluid in two groups were significantly decreased (P<0.05), and these factors in the treatment group were significantly lower than those in the control group (P<0.05). During the treatment, the adverse reactions rate in the control group was 10.98%, which was significantly higher than 2.41% in treatment the group, with significant difference between two groups (P<0.05). Conclusion Longqing Tablets combined with norfloxacin is effective and safe in treatment of chronic prostatitis, which has a certain clinical application value.